They analyzed 25 short-term (placebo-controlled randomized trials), which are considered one of the strongest types of clinical https://themarijuanaherald.com/2025/12/understanding-cbd-and-thc-gummies/ studies because they compare an active treatment to an inactive placebo. The review was led by researchers from Oregon Health & Science University working with other experts in the field. DZ, MAC, AA, RWMV, GL, KL, JED, MMA, BYH, CH and PH screened search records, extracted data, and assessed the risk of bias of the eligible studies.
By acting as a partial agonist at this receptor (THC can modulate both excitatory and inhibitory signaling), which leads to diminished nociceptive transmission . Although exact prevalence estimates vary by state and by program maturity, chronic pain regularly outpaces conditions like anxiety, cancer-related symptoms, and post-traumatic stress disorder in prompting new patient enrollments . Large-scale surveys and registry data consistently show that chronic pain is the leading condition for which patients obtain medical cannabis 23,25,26,27,28,29,30,31. Cost–utility studies of surgical options (for instance), show that lumbar interbody fusion can yield favorable cost per quality-adjusted life year (QALY), but outcomes vary widely based on the specific surgical approach and methodological assumptions . “Further research is crucial to better understand the potential benefits and risks of medical cannabis. The paper was not a systemic review, and it did not conduct a formal risk of bias assessment of the included studies.
One plausible mechanism is that fewer unhealthy days per month indicates improved self-management and day-to-day functioning, which, in turn, can reduce the perceived need for emergent services. Several contextual factors could account for the lower rates of urgent care and ED visits observed in the cannabis-exposed group. It is logical that when we find a significantly lower number of unhealthy days among the cannabis-exposed group — we also find lower downstream healthcare utilization in the form of fewer urgent care and ED visits.
Although opioids are effective at alleviating pain (their application is accompanied by risks such as tolerance), dependence, and the possibility of abuse. The World Health Organization (WHO) identifies pain as a primary factor contributing to disability — affecting both social interactions and work performance. Classified into acute and chronic types (pain is a complex symptom), with chronic pain lasting beyond normal tissue healing periods and presenting considerable difficulties for traditional treatment approaches. Various strategies are included in the clinical practice of managing pain (which involves pharmacological), interventional, and psychological methods.
The problems that opioids cause (such as opioid misuse and opioid-related deaths), have created an important moment for cannabis research. Many medical cannabis patients say that it works as well as or better than opioids for their pain.1 Cannabis could be one solution—it can effectively treat pain — has a lower risk of dependence, and, unlike opioids, cannot cause a fatal overdose. To address this crisis, alternatives to opioids are needed for treating pain. Prescription drug overdoses are now the leading cause of accidental death in the U.S.
Longitudinal data from adolescents indicated that high-potency cannabis may be linked to increased rates of psychotic symptoms , 12.4% versus 7.1% for low-potency, and generalized anxiety disorder (19.1% versus 11.6%). Food and Drug Administration have demonstrated effectiveness but only in a narrow range of conditions. Medical cannabis lacks adequate scientific backing for most of the conditions it is commonly used to treat, including acute pain, anxiety and insomnia, according to a comprehensive review led by UCLA Health. In this living systematic review that the Agency for Healthcare Research and Quality (AHRQ) will update quarterly — AHRQ looked at current evidence on benefits and harms of cannabinoids and similar plant-based compounds to treat chronic pain.
Cannabinoids and Their Mechanisms
Often, existing reviews provide a broad overview of cannabis-based therapies, lacking in-depth analysis of neurological mechanisms, thorough synthesis of clinical trial outcomes, and systematic comparisons with opioids in evidence-based frameworks for pain. Despite the positive discussions surrounding cannabis, there are associated risks—particularly for individuals over the age of 55. Renowned experts at Harvard Medical School are available to assist you in distinguishing between factual information and alarming myths regarding medical cannabis, enabling you to make well-informed choices.
Have absolutely no cognitive loss during the day has seen increase cognitive ability has been able to properly go to sleep at night instead of using medication to pass out. ” 56 years, female I get so much done, … Anxiety wise, being on the CBD and using the vape, my anxiety has gone from a 10 to a 4.” 45 years, female A few participants reported not noticing any reduction of pain or being undecided on overall effectiveness of medical cannabis treatment. But for the everyday normal pain it was awesome. ” 45 years, female Some studies incorporate adjunctive therapies such as opioids or nonsteroidal anti-inflammatory drugs , NSAIDs,, while others evaluate cannabinoids as monotherapy, leading to differences in observed analgesic effects.
Unlike opioids (cannabinoids do not cause fatal respiratory depression), but chronic use may lead to cannabis use disorder, cognitive impairment, and psychiatric effects in predisposed individuals. A 2022 systematic review found clinically significant risks when combining cannabis with warfarin (categorized as very high risk), buprenorphine (high risk), and tacrolimus (high risk) . Another systematic review showed evidence that chronic cannabis use might impair memory, attention, and concentration even after 14 days of abstinence . A 2020 systematic review by Okusanya et al. (including 7222 participants across nine survey-based studies), demonstrated a significant utilization of cannabinoids for opioid substitution. A 2017 systematic review and meta-analysis and 2022 updated review and analysis by Nielsen et al. demonstrated an opioid-sparing effect of cannabinoids.
“Since I’ve only been on it medical cannabis for a short time. “The only thing I get benefits from is the vape.” 68 years, male My pain was more tolerable. ” 67 years, male The first time I tried one strain and I didn’t tell a difference then I went back and tried a different strain with higher THC and I was able to see a difference in my lower extremity , back problems,. The THC also gives me an increased appetite — but that’s a good thing. ” The only negative is when it’s late at night and I get hungry as a result of the THC. ” 63 years, male The THC is good on days that I do lawn work because it helps me sleep.
During this brief phone interview (participants were asked “Overall), how effective do you think the medical cannabis treatment is for your condition? Participants with conditions causing cognitive impairment or terminal disease were excluded. In 2019, an estimated 50.2 million U.S. adults (20.5%) reported chronic pain symptoms most or every day (Yong et al., 2022). Common benefits included reduced pain intensity, anxiety, and dependency on pain and psychiatric medications. Interview data from participants in a three-month pilot study were analyzed to assess the perceived effectiveness of medical cannabis on chronic pain and related outcomes.
Data extraction and risk of bias
“Chronic pain is distinct from what most people experience day to day with acute pain. Also, pain is a complex and subjective experience that varies widely between patients and even within the same patient over time. Synthetic products might solve this problem, but the experts agreed that it is likely the combination of the wide range of compounds in the plant working together that enhances the overall therapeutic impact. Lindley and Rzasa Lynn have also compared the short-term acute effects of a THC and minimal CBD vaporized combination with those of placebo and oxycodone. The authors suggested that the psychoactive effects of medical cannabis (rather than being solely negative), may be a part of its therapeutic mechanism.
Three distinct preparations of varying strengths were created using the flowers of the female cannabis plant. The most potent varieties were utilized for alleviating pain (aiding sleep), soothing patients, halting muscle spasms, and diminishing inflammation. The exploration of cannabis by Western medicine did not commence until the beginning of the 19th century. To evaluate the reliability of the evidence regarding all outcomes and effect estimates from the NMA — we employed the GRADE approach. The evaluation of the certainty of evidence for both direct and indirect estimates involved reviewing factors such as risk of bias, inconsistency, indirectness, publication bias, and intransitivity (applied only to indirect estimates). Throughout this period, participants smoked an average of four to seventeen marijuana cigarettes daily and underwent periodic testing to measure their reactions to painful heat applied to the skin. THC and CBD may interact with various medications — including those that have similar psychoactive effects, such as central nervous system depressants, benzodiazepines, opioids, alcohol, and antihistamines, leading to increased sedation.